Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Dr. Weiss's "Highlights in Lung Cancer, 2011": CT Screening & Optimal Management of Elderly Patients with Advanced NSCLC
Dr West
Author
Howard (Jack) West, MD

This is the third and final part of Dr. Weiss's presentation on "Highlights in Lung Cancer, 2011".  After focusing on developments in relatively narrow subpopulations with distinct molecular markers in the first two parts of his webinar, Dr. Weiss closed with his coverage of a couple of issues with broader applicability: the new data supporting CT screening for higher risk people with a significant smoking history, and also some new data addressing the question of whether elderly patients are best served by receiving single agent or doublet chemotherapy.

Below you'll find the podcast of the program in audio and video formats, as well as the transcript and figures for this activity.

[powerpress]

Dr. Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Audio Podcast

Dr. Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Transcript

Dr Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Figs

The last component of this program will be the Q&A session, which we'll be releasing in just a few days.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

Recent Comments

JOIN THE CONVERSATION
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on